Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Niagen Bioscience (NAGE) FCF Margin (2016 - 2025)

Niagen Bioscience (NAGE) has disclosed FCF Margin for 13 consecutive years, with 1.71% as the latest value for Q4 2025.

  • Quarterly FCF Margin fell 2752.0% to 1.71% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 10.21% through Dec 2025, down 179.0% year-over-year, with the annual reading at 10.21% for FY2025, 179.0% down from the prior year.
  • FCF Margin for Q4 2025 was 1.71% at Niagen Bioscience, down from 10.79% in the prior quarter.
  • The five-year high for FCF Margin was 29.23% in Q4 2024, with the low at 46.1% in Q2 2021.
  • Average FCF Margin over 5 years is 5.91%, with a median of 1.43% recorded in 2024.
  • The sharpest move saw FCF Margin tumbled -3653bps in 2021, then skyrocketed 5383bps in 2023.
  • Over 5 years, FCF Margin stood at 27.85% in 2021, then skyrocketed by 91bps to 2.38% in 2022, then surged by 224bps to 2.96% in 2023, then soared by 887bps to 29.23% in 2024, then plummeted by -94bps to 1.71% in 2025.
  • According to Business Quant data, FCF Margin over the past three periods came in at 1.71%, 10.79%, and 3.58% for Q4 2025, Q3 2025, and Q2 2025 respectively.